Product Name: COL9A1 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 92 kDa
Immunogen: This COL9A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 428-456 amino acids from the Central region of human COL9A1.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 98-92-0
Product: Nicotinamide
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Collagen alpha-1(IX) chain, COL9A1
Accession NO.: P20849
Protein Ino: 296439373
Official Symbol: COL9A1
Geneid: 1297
Background: COL9A1 is one of the three alpha chains of type IX collagen, which is a minor (5-20%) collagen component of hyaline cartilage. Type IX collagen is usually found in tissues containing type II collagen, a fibrillar collagen. Studies in knockout mice have shown that synthesis of the alpha 1 chain is essential for assembly of type IX collagen molecules, a heterotrimeric molecule,and that lack of type IX collagen is associated with early onset osteoarthritis. Mutations in the COL9A1 gene are associated with osteoarthritis in humans, with multiple epiphyseal dysplasia, 6, a form of chondrodysplasia, and with Stickler syndrome, a disease characterized by ophthalmic, orofacial, articular, and auditory defects.
PubMed ID:http://aac.asm.org/content/36/10/2334.abstract
